Georgetown Lombardi Clinical Trial Helps Advance Use of Immunotherapy in Liver Cancer
May 29th, 2020
In August of 2016, Dan Hilton arrived at MedStar Georgetown University Hospital to be evaluated for a liver transplant. He had been diagnosed with cirrhosis, the result of a hepatitis C infection contracted many years earlier. After multiple tests, he received unexpected news; the doctors found tumors on his liver.
Indivumed Global Alliance to Broaden Access to Multi-Omics Algorithms, Precision Medicine Education
May 4th, 2020
Germany-based Indivumed is enlisting the help of cancer centers and research institutions around the world to help expand its omics database and make it a key resource for unraveling the complexities of cancer biology and advancing new precision oncology drugs. Indivumed last month launched the Oncology Alliance for Individualized Medicine (Onco AI-Med), which is a partnership between leading cancer clinics and research institutions selected based on their research activities and expertise in molecularly informed cancer care. Currently, the collaboration includes over 30 partners from 11 countries, though Indivumed plans to add new sites to the alliance continuously.
Colorectal cancer care in the age of coronavirus: strategies to reduce risk and maintain benefit
April 16th, 2020
We are in unprecedented times requiring us to approach our medical obligations in unprecedented ways. Cancer care is not elective and therefore must be maintained throughout the COVID-19 pandemic. However, we recognize that there is early evidence based on small studies from China and Italy that cancer patients are at increased risk of severe illness if they are to develop a COVID-19 infection and there is even some evidence to suggest that healthcare providers are at increased risk, possibly due to exposure to larger viral loads and repeated exposure…
FDA Approves Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma
March 19th, 2020
“The approval of nivolumab and ipilimumab in the second-line treatment of advanced HCC means we will have a combination immune therapy option in patients who have progressed on frontline therapy. The overall survival (OS) of nivolumab and ipilimumab in the second-line treatment of advanced HCC as shown in CheckMate-040 was very promising, so far the longest duration of OS in the second-line setting for advanced-stage HCC, tested in clinical trials,” said Aiwu Ruth He, MD, PhD, associate professor of Medical Oncology at Georgetown University.
Targeted Therapies Showing Promise in Colorectal Cancer
February 6th, 2020
Benjamin Weinberg, MD, assistant professor of medicine and attending physician at MedStar Georgetown University Hospital, Washington, DC, discusses novel agents that may impact the treatment landscape for colorectal cancer (CRC) once made available in the community setting.
